IRVINE, Calif.--(BUSINESS WIRE)--Mar. 4, 2019--
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical
technology company focused on the development and commercialization of
novel implantable Sacral Neuromodulation (“SNM”) devices for the
treatment of urinary
and bowel dysfunction, today announced that Michael H. Carrel has
been appointed to the Axonics board of directors, effective immediately.
Mr. Carrel has served as the president and CEO and member of the board
of AtriCure, Inc. (NASDAQ: ATRC) since late 2012. AtriCure is a medical
device company with over 600 employees that develops and markets
products for the treatment of atrial fibrillation and related
conditions. AtriCure’s current market capitalization is approaching $1.3
billion with 2018 revenue of $202 million, up from $72 million in 2012.
Mr. Carrel’s 25-year career includes successful leadership in global
organizations in the healthcare and technology industries. Before
joining AtriCure, Mr. Carrel was president and CEO of Vital Images, a
publicly-traded medical imaging software company which was acquired by
Toshiba Medical Systems Corporation. Prior to Vital Images, Mr. Carrel
was president and CEO of Zamba Corp., a publicly-traded technology
company, and CFO of NextNet Wireless, a provider of non-line-of-sight
plug and play broadband wireless access systems. Mr. Carrel serves on
the board of the Medical Device Manufacturers Association (MDMA). He
earned a B.S. in Accounting from The Pennsylvania State University and
an M.B.A. from the Wharton School at the University of Pennsylvania.
Concurrent with this appointment, John Petrovich, a member of the board
of directors since the Company’s inception, has retired from the Axonics
board and will not stand for re-election at the Axonics annual
shareholder meeting planned for August 19, 2019.
Raphael Wisniewski, chairman of the board of Axonics, said, “On behalf
of all stakeholders at Axonics, we thank Mr. Petrovich for his board
service over the past five years. The intellectual property that Axonics
licensed from the Alfred Mann Foundation (‘the AMF’), where John serves
as CEO, has proven to be invaluable to Axonics. We all owe a debt of
gratitude to John and AMF for their foresight to place the AMF assets in
the hands of the Axonics management team.”
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and
commercialization of a novel implantable SNM system for patients with
urinary and bowel dysfunction. The Axonics r-SNM® System is the first
rechargeable Sacral Neuromodulation system approved for sale in Europe,
Canada and Australia, and the first SNM system to gain CE mark for
full-body MRI conditional labeling. Premarket Approval (PMA) for the
r-SNM System is currently pending with the U.S. FDA. For more
information, visit the Company’s website at www.axonicsmodulation.com.
Forward-Looking Statements
Statements made in this press release that relate to future plans,
events, prospects or performance are forward-looking statements as
defined under the Private Securities Litigation Reform Act of 1995.
Words such as “planned,” “expects,” “believes,” “anticipates,”
“designed,” and similar words are intended to identify forward-looking
statements. While these forward-looking statements are based on the
current expectations and beliefs of management, such forward-looking
statements are subject to a number of risks, uncertainties, assumptions
and other factors that could cause actual results to differ materially
from the expectations expressed in this press release, including the
risks and uncertainties disclosed in Axonics filings with the Securities
and Exchange Commission, all of which are available online at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Except as required by law, Axonics undertakes no obligation to update or
revise any forward-looking statements to reflect new information,
changed circumstances or unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005121/en/
Source: Axonics Modulation Technologies, Inc.
Axonics’ Contact
Axonics Modulation Technologies, Inc.
Dan
Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com
Investor & Media Contact
W2Opure
Matt Clawson,
+1-949-370-8500
mclawson@w2ogroup.com
